Breast cancer incidence and mortality in the Nordic capitals, 1970–1998. Trends related to mammography screening programmes

2006 ◽  
Vol 45 (5) ◽  
pp. 528-535 ◽  
Author(s):  
Sven Törnberg ◽  
Levent Kemetli ◽  
Elsebeth Lynge ◽  
Anne Helene Olsen ◽  
Solveig Hofvind ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Incidence ◽  
Mammography Screening ◽  
Breast Cancer Incidence ◽  
Incidence And Mortality

scholarly journals Radiation-Induced Breast Cancer Incidence and Mortality From Digital Mammography Screening

2016 ◽  
Vol 164 (4) ◽  
pp. 205 ◽  
Author(s):  
Diana L. Miglioretti ◽  
Jane Lange ◽  
Jeroen J. van den Broek ◽  
Christoph I. Lee ◽  
Nicolien T. van Ravesteyn ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Incidence ◽  
Digital Mammography ◽  
Mammography Screening ◽  
Breast Cancer Incidence ◽  
Incidence And Mortality ◽  
Radiation Induced

scholarly journals Breast cancer incidence and mortality in Tyrol/Austria after fifteen years of opportunistic mammography screening

2010 ◽  
Vol 10 (1) ◽  
Author(s):  
Willi Oberaigner ◽  
Wolfgang Buchberger ◽  
Thomas Frede ◽  
Rudolf Knapp ◽  
Christian Marth ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Incidence ◽  
Mammography Screening ◽  
Breast Cancer Incidence ◽  
Incidence And Mortality

scholarly journals Is mammography screening beneficial: An individual-based stochastic model for breast cancer incidence and mortality

2020 ◽  
Author(s):  
Thuy T. T. Le ◽  
Frederick R. Adler
Keyword(s):  
Breast Cancer ◽  
Cancer Progression ◽  
Cancer Incidence ◽  
Mammography Screening ◽  
Mechanistic Model ◽  
Breast Cancer Incidence ◽  
Published Data ◽  
National Breast ◽  
Incidence And Mortality ◽  
Screening Study

AbstractBACKGROUNDThe benefits of mammography screening have been controversial, with conflicting findings from various studies.METHODSWe hypothesize that unmeasured heterogeneity in tumor aggressiveness underlies these conflicting results. Based on published data from the Canadian National Breast Screening Study (CNBSS), we develop and parameterize an individual-based mechanistic model for breast cancer incidence and mortality that tracks five stages of breast cancer progression and incorporates the effects of age on breast cancer incidence and all-cause mortality.RESULTSThe model accurately reproduces the reported outcomes of the CNBSS. By varying parameters, we predict that the benefits of mammography depend on the effectiveness of cancer treatment and tumor.CONCLUSIONSIn particular, patients with the most rapidly growing or potentially largest tumors have the highest benefit and least harm from the screening, with only a relatively small effect of age. However, the model predicts that confining mammography populations with a high risk of acquiring breast cancer increases the screening benefit only slightly compared with the full population.

scholarly journals Comparing CISNET Breast Cancer Incidence and Mortality Predictions to Observed Clinical Trial Results of Mammography Screening from Ages 40 to 49

2018 ◽  
Vol 38 (1_suppl) ◽  
pp. 140S-150S ◽  
Author(s):  
Jeroen J. van den Broek ◽  
Nicolien T. van Ravesteyn ◽  
Jeanne S. Mandelblatt ◽  
Hui Huang ◽  
Mehmet Ali Ergun ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Incidence ◽  
Cancer Mortality ◽  
Mammography Screening ◽  
Breast Cancer Mortality ◽  
Breast Cancer Incidence ◽  
Mortality Reduction ◽  
Incidence And Mortality ◽  
The Uk

Background. The UK Age trial compared annual mammography screening of women ages 40 to 49 years with no screening and found a statistically significant breast cancer mortality reduction at the 10-year follow-up but not at the 17-year follow-up. The objective of this study was to compare the observed Age trial results with the Cancer Intervention and Surveillance Modeling Network (CISNET) breast cancer model predicted results. Methods. Five established CISNET breast cancer models used data on population demographics, screening attendance, and mammography performance from the Age trial together with extant natural history parameters to project breast cancer incidence and mortality in the control and intervention arm of the trial. Results. The models closely reproduced the effect of annual screening from ages 40 to 49 years on breast cancer incidence. Restricted to breast cancer deaths originating from cancers diagnosed during the intervention phase, the models estimated an average 15% (range across models, 13% to 17%) breast cancer mortality reduction at the 10-year follow-up compared with 25% (95% CI, 3% to 42%) observed in the trial. At the 17-year follow-up, the models predicted 13% (range, 10% to 17%) reduction in breast cancer mortality compared with the non-significant 12% (95% CI, -4% to 26%) in the trial. Conclusions. The models underestimated the effect of screening on breast cancer mortality at the 10-year follow-up. Overall, the models captured the observed long-term effect of screening from age 40 to 49 years on breast cancer incidence and mortality in the UK Age trial, suggesting that the model structures, input parameters, and assumptions about breast cancer natural history are reasonable for estimating the impact of screening on mortality in this age group.

Breast Cancer

2018 ◽  
Author(s):  
Nancy E Davidson
Keyword(s):  
Breast Cancer ◽  
United States ◽  
Cancer Incidence ◽  
Hormone Replacement ◽  
Breast Cancer Incidence ◽  
Stage Iv ◽  
The United States ◽  
Rate Of Increase ◽  
Stage Iv Breast Cancer ◽  
Incidence And Mortality

Invasive breast cancer, the most common nonskin cancer in women in the United States, will be diagnosed in 266,120 In 2018, along with 63,960 new cases of non-invasive (in situ) breast cancer. Incidence and mortality reached a plateau and appear to be dropping in both the United States and parts of western Europe. This decline has been attributed to several factors, such as early detection through the use of screening mammography and appropriate use of systemic adjuvant therapy, as well as decreased use of hormone replacement therapy. However, the global burden of breast cancer remains great, and global breast cancer incidence increased from 641,000 in 1980 to 1,643,000 in 2010, an annual rate of increase of 3.1%. This chapter examines the etiology, epidemiology, prevention, screening, staging, and prognosis of breast cancer. The diagnoses and treatments of the four stages of breast cancer are also included. Figures include algorithms used for the systemic treatment of stage IV breast cancer and hormone therapy for women with stage IV breast cancer. Tables describe selected outcomes from the National Surgical Adjuvant Breast and Bowel Project (NSABP) P-1 and P-2 chemoprevention trials, tamoxifen chemoprevention trials for breast cancer, the TNM staging system and stage groupings for breast cancer, some commonly used adjuvant chemotherapy regimens, an algorithm for suggested treatment for patients with operable breast cancer from the 2011 St. Gallen consensus conference, guidelines for surveillance of asymptomatic early breast cancer survivors from the American Society of Clinical Oncology, and newer agents for metastatic breast cancer commercially available in the United States. This review contains 2 highly rendered figures, 8 tables, and 108 references.

Sign in / Sign up

Export Citation Format

Share Document